Schizophrenia Trial, Recruiting NCT05276050 Sponsor: The University of Texas Health Science Center, Houston Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT05276050
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 22 and 65 years, of any gender
  • People who are able to read and sign a consent form agreeing to take part
  • People who have smoked for at least one year and have smoked an average of 5 or more cigarettes per day over the past 4 weeks
  • People who have been diagnosed with a schizophrenia-spectrum disorder and who score above 10 on a specific consent-ability assessment (confirm with trial site)
  • People who are currently receiving care from a licensed doctor, psychiatrist, psychologist, nurse practitioner, or clinical social worker
  • People who agree to allow the research team to communicate with their current or recent healthcare providers, and who can provide contact details for at least two people aged 22 or older who live within a 30-minute drive of their home and who the research staff may contact during the study if needed

Who may not be able to join:

  • People who have a close family member (parent, sibling, or child) with inherited epilepsy or seizures, or people who answer "yes" to certain questions on an epilepsy screening questionnaire
  • People who have received any treatment to help them stop smoking, taken part in a related clinical trial, or used nicotine replacement products within the past 4 weeks
  • People who have had significant problems with alcohol or drugs other than nicotine or marijuana within the past 6 months (or drug misuse within the past month)
  • People who have a major medical condition that may affect normal brain function, such as a history of stroke, brain infection, or brain tumour
  • People who are taking more than 400 mg per day of the medication clozapine, or who do not pass a specific screening questionnaire related to the brain stimulation method used in this trial
  • People who have a cardiac pacemaker, implanted medication pump, intracardiac lines, unstable heart disease, or any metal implants in or near the head (such as aneurysm clips, cochlear implants, or stimulators) that cannot be safely removed
  • People who have had a head injury that caused loss of consciousness for more than 10 minutes, or who have had brain surgery
  • People who are unable to avoid using alcohol or marijuana for 24 or more hours, or cigarettes for 1 or more hours, before study sessions
  • Women who are pregnant, may be pregnant, or who have had unprotected sex without contraception in the past 4 weeks
  • People assessed as being at moderate to high risk of suicide based on a specific suicide risk assessment tool, or based on the judgement of the study doctor
  • People who, in the medical opinion of the study investigator, have circumstances or conditions that may increase the risk of seizures — this includes a range of medical, medication, and lifestyle factors (confirm with trial site for the full list)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiaoming Du, PhD, The University of Texas Health Science Center, Houston

Phone: 443-882-9717

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 June 2022
Est. completion
28 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Resting-state functional connectivity (rsFC) from functional magnetic resonance imaging (fMRI); Cigarette per day

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov